Cartesian Therapeutics, Inc.

8 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Selecta Biosciences, Inc. (to 2024)

Ending by 2030

May 2034

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 15, 2027.

Recent changes

1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Patent	Title	Status	Expires	Confidence
US 12,508,249	Methods Related to Administering Immunosuppressants and Non-Allergenic Antigens to Reduce or Prevent Anaphylaxis In force Term ends May 2, 2034 · Medium confidence	In force	Term ends May 2, 2034	Medium confidence
US 12,472,167	Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity In force Term ends May 27, 2035 · From the USPTO record	In force	Term ends May 27, 2035	From the USPTO record
US 12,194,078	Methods and Compositions Related to Combined Treatment with Anti-Inflammatories and Synthetic Nanocarriers Comprising an Immunosuppressant In force Term ends Mar 11, 2038 · High confidence	In force	Term ends Mar 11, 2038	High confidence
US 10,934,337	Anti-Bcma Chimeric Antigen Receptors In force Term ends Mar 13, 2040 · Medium confidence	In force	Term ends Mar 13, 2040	Medium confidence
US 11,220,535	Anti-Bcma Chimeric Antigen Receptors In force Ends no later than Mar 13, 2040 · Low confidence	In force	Ends no later than Mar 13, 2040	Low confidence
US 11,999,773	Anti-Bcma Chimeric Antigen Receptors In force Ends no later than Apr 2, 2040 · Low confidence	In force	Ends no later than Apr 2, 2040	Low confidence
US 12,553,041	Formulations and Doses of Pegylated Uricase In force Term ends Jun 13, 2040 · High confidence	In force	Term ends Jun 13, 2040	High confidence
US 12,709,739	Engineered Cells Secreting Therapeutic Enzymes In force Term ends Aug 25, 2043 · High confidence	In force	Term ends Aug 25, 2043	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

7 pending · 1 no status recorded

List them